Chinese Drugmaker Agrees to Buy Out Singapore Biotech SciGen
Chinese drug maker Yifan Pharmaceutical Co. agreed to acquire a controlling stake in the Singapore biopharmaceutical company SciGen Ltd. in a deal worth as much as $28 million, the Zhenjiang-based company said in an exchange filing Wednesday.
Yifan offered $0.05 a share to acquire at least 90% of Australian Stock Exchange-listed SciGen in an effort to take the company private. A full takeover would value SciGen at $28 million, according to Yifan.
- 1 China Seeks $7 Billion Sanctions Against U.S. in Dumping Dispute
- 2Opinion: China-U.S. Friendship Goes Deeper Than Fights Over Trade, Pollution
- 3With Latest IPhones, Apple Again Bows to the Chinese Market
- 4Chinese Scientist Blasts U.S. Over Politicization of Research
- 5Gallery: Xi’an’s War on ‘Illegal’ Villas Thunders On
- 1Power To The People: Pintec Serves A Booming Consumer Class
- 2Largest hotel group in Europe accepts UnionPay
- 3UnionPay mobile QuickPass debuts in Hong Kong
- 4UnionPay International launches premium catering privilege U Dining Collection
- 5UnionPay International’s U Plan has covered over 1600 stores overseas